Results 31 to 40 of about 13,844,580 (194)

PBPK modeling: What is the role of CYP3A4 expression in the gastrointestinal tract to accurately predict first‐pass metabolism?

CPT: Pharmacometrics & Systems Pharmacology
Gastrointestinal first‐pass metabolism plays an important role in bioavailability and in drug–drug interactions. Physiologically‐based pharmacokinetic (PBPK) modeling is a powerful tool to integrate these processes mechanistically.
Justine Henriot, André Dallmann, François Dupuis, Jérémy Perrier, Sebastian Frechen   +4 more
doaj   +1 more source

Development of a multi-route physiologically based pharmacokinetic (PBPK) model for nanomaterials: a comparison between a traditional versus a new route-specific approach using gold nanoparticles in rats

Particle and Fibre Toxicology, 2022
Background Physiologically based pharmacokinetic (PBPK) modeling is an important tool in predicting target organ dosimetry and risk assessment of nanoparticles (NPs).
Wei-Chun Chou, Yi-Hsien Cheng, Jim E. Riviere, Nancy A. Monteiro-Riviere, Wolfgang G. Kreyling, Zhoumeng Lin   +5 more
doaj   +1 more source

Non‐Invasively Quantitative Raman Imaging for Calculation of Lymphatic Transport Kinetics of Micelles in Mice

Advanced Science, EarlyView.
Non‐invasively quantitative Raman imaging with stacking‐induced charge transfer‐enhanced Raman scattering (SICTERS) enables accurate measurement of concentrations and pharmacokinetic modeling of lymphatic transport of micelles in mice. This platform allows dynamic analysis of nanoparticle transport and underpins the design of effective lymph node ...
Yunlu Li, Hongzheng Lin, Sheng Yu, Yunhui Liao, Teng Huang, Zeyu Xiao, Wei Lu   +6 more
wiley   +1 more source

Integrated multi-scale PBPK/PD model.

, 2019
From left to right: Whole-body model (PBPK): The drug distribution is modelled using the PBPK approach at the level of the human whole-body. Integrated model (PBPK/PD): The integrated model encompasses the dose arriving from the whole-body PBPK model to ...
Jörg Lippert (124210), Julian Brandl (3840103), Sven Sahle (222858), Lars Küpfer (6331121), Priyata Kalra (6331118), Christoph Niederalt (535381), Ursula Kummer (437648), Thomas Gaub (223638)   +7 more
core   +1 more source

A Systematic Review of Published Physiologically Based Pharmacokinetic Models for Drug Excretion Into Human Breastmilk: Knowledge Gaps and Opportunities to Optimize Reporting and Modeling Practices

CPT: Pharmacometrics & Systems Pharmacology
Physiologically based pharmacokinetic (PBPK) modeling is increasingly used to predict infant exposure to medications via breast milk. Existing guidance on reporting of PBPK modeling analyses is unstructured and nonbinding to researchers.
Joshua Kiptoo, Davies Otieno, Kenta Yoshida, Neel Deferm, Aida Nakayiwa Kawuma, Francis Williams Ojara, Adeniyi Olagunju, Jackson K. Mukonzo, Catriona Waitt   +8 more
doaj   +1 more source

Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict CYP3A-Mediated Drug Interaction between Saxagliptin and Nicardipine: Bridging Rat-to-Human Extrapolation

Pharmaceutics
The aim of this study was to predict the cytochrome P450 3A (CYP3A)-mediated drug–drug interactions (DDIs) between saxagliptin and nicardipine using a physiologically based pharmacokinetic (PBPK) model.
Jeong-Min Lee, Jin-Ha Yoon, Han-Joo Maeng, Yu Chul Kim   +3 more
doaj   +1 more source

Optimizing Cancer Vaccinations Using a Physiologically‐Based Pharmacokinetic/Pharmacodynamic (PBPK/PD) Model

Advanced Science, EarlyView.
Where and when should a cancer vaccine be administered? A whole‐body PBPK model demonstrates that systemic immune transport critically determines vaccination efficacy. By simulating how organ‐specific immune interactions influence treatment response, the study provides a quantitative framework for optimizing cancer vaccination strategies.
Mohammad R. Nikmaneshi, Timothy P. Padera, Lance L. Munn   +2 more
wiley   +1 more source

Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically‐Based Pharmacokinetic Modeling

Clinical and Translational Science, 2021
Sjögren’s syndrome (SS) is an autoimmune disease with no effective treatment options. Resolvin D1 (RvD1) belongs to a class of lipid‐based specialized pro‐resolving mediators that showed efficacy in preclinical models of SS.
Venkata K. Yellepeddi, Kaustubh Parashar, Spencer M. Dean, Kevin M. Watt, Jonathan E. Constance, Olga J. Baker   +5 more
doaj   +1 more source

Autonomous AI‐Driven Design for Skin Product Formulations

Advanced Intelligent Discovery, EarlyView.
This review presents a comprehensive closed‐loop framework for autonomous skin product formulation design. By integrating artificial intelligence‐driven experiment selection with automated multi‐tiered assays, the approach shifts development from trial‐and‐error to intelligent optimisation.
Yu Zhang, Yongrui Xiao, Chunlin Chen, Dimitrios Tsaoulidis, Kai Yang, Tao Chen   +5 more
wiley   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source